Revolution Medicines, Inc. Common Stock (RVMD) Financials

Key financial figures for Revolution Medicines, Inc. Common Stock (Q3 2026).

Revolution Medicines, Inc. reported revenue of $197.6 million for Q3 FY2026. The company posted a net loss of $407.5 million, or -$1.90 per share. Operating margin came to -188.88%. Free cash flow for the period was -$419.3 million. The figures above are as filed, and the full income statement, balance sheet and cash flow history for Revolution Medicines, Inc. are on the SentiSense financials page.

Revenue
$198M
Net Income
-$407M
EPS
$-1.90
Total Assets
$4.3B
Operating Cash Flow
-$416M

Recent quarters

PeriodRevenueNet IncomeEPSOperating MarginFree Cash Flow
Q3 FY2026$198M-$407M-$1.90-188.88%-$419M
Q2 FY2026$0-$644M-$3.06-$390M
Q1 FY2026$0-$454M-$2.29-$356M
Q4 FY2025$0-$365M-$1.90-$276M
Q3 FY2025$0-$305M-$1.61-$211M

Recent fiscal years

PeriodRevenueNet IncomeEPSOperating MarginFree Cash Flow
FY2025$0-$1.1B-$5.95-$914M
FY2024$0-$600M-$3.58-$568M
FY2023$12M-$436M-$3.86-4207.12%-$358M

Frequently asked questions

What was Revolution Medicines, Inc.'s revenue last quarter?

Revolution Medicines, Inc. reported revenue of $197.6 million for Q3 FY2026.

Is Revolution Medicines, Inc. profitable?

Not in its most recent reported period. Revolution Medicines, Inc. reported a net loss of $407.5 million for Q3 FY2026, a net margin of -206.25% on revenue.

How has Revolution Medicines, Inc.'s margin trended?

Operating margin was -188.88% in Q3 FY2026. The quarter by quarter series is on the SentiSense financials page.

How much free cash flow did Revolution Medicines, Inc. generate?

Revolution Medicines, Inc. generated free cash flow of -$419.3 million in Q3 FY2026, after capital expenditure.

Full income statement, balance sheet and cash flow for Revolution Medicines, Inc. Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.